Dihexa
A neuropeptide showing regenerative effects in animal models of Alzheimer's and neurological injury, with no human trials.
Peptides
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Dihexa
A neuropeptide showing regenerative effects in animal models of Alzheimer's and neurological injury, with no human trials.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
Dihexa is a peptide with neuroregenerative properties being investigated for neurological disorders including stroke and traumatic brain injury. In preclinical models, dihexa promotes neuronal regeneration, increases dendritic spines and synaptic connections, and improves cognition. In one rat model of Alzheimer's disease, dihexa restored cognitive performance, reportedly outperforming donepezil (Aricept), a standard dementia medication. Despite these promising preclinical findings, dihexa has never been advanced into formal human clinical trials. No long-term safety studies in any species have been published.
Benefits reported in the imported source
- Promotes neuronal regeneration and synaptic development in preclinical models
- Improved cognitive performance in rat models of Alzheimer's disease
Risks and limits
- No human clinical trials have been conducted
- Not FDA-approved and has not been formally developed as a therapeutic
- Long-term safety in any species has not been studied
- Preclinical effects may not translate to human benefit
Source bottom line: Dihexa shows neuroprotective and regenerative effects in animal research, but has never been tested in humans and is not an approved therapeutic.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Dihexa Protocol Guide — Dosing, Reconstitution & Administration - Path To Peptides
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A neuropeptide protocol guide describes oral dihexa dosing at 10–20 mg initiated once weekly, with titration to 50–100 mg weekly as tolerated.
Dihexa Protocol Guide — Dosing, Reconstitution & Administration - Path To Peptides
Unverified imported account — Dihexa Protocol Guide — Dosing, Reconstitution & Administration - Path To Peptides
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: The same guide recommends structuring dihexa use as 4–8 weeks on followed by 4 weeks off due to the compound's extended duration of action and potential for accumulation.
Dihexa Protocol Guide — Dosing, Reconstitution & Administration - Path To Peptides
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
- Dihexa
- Dihexa Peptide: Unlocking Brain Repair, Focus, and Memory
- Hepatocyte growth factor mimics as therapeutic agents (availability check 2026-10-15: retrieval failed; no access or certificate warning bypassed)
Snapshot provenance
Source ID: catalog:peptide:dihexa. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.